Literature DB >> 16155023

Molecular pathogenesis of Hodgkin's lymphoma.

Daniel Re1, Ralf Küppers, Volker Diehl.   

Abstract

According to the WHO classification, Hodgkin's lymphoma (HL) is subdivided into a classical variant and a nodular lymphocyte predominant variant which are characterized by the presence of Hodgkin's and Reed-Sternberg (H-RS) cells or lymphocytic and histiocytic (L&H) cells, respectively. This article reviews genetic characteristics and transcriptional changes of H-RS and L&H cells, including recent knowledge about transforming mechanisms and signaling pathways that contribute to the antiapoptotic phenotype displayed by H-RS and L&H cells. We also discuss major cellular and molecular mediators contributing to the establishment and maintenance of a reactive background in HL-affected tissues. We believe that an in-depth understanding of the pathogenesis of HL will eventually lead to the development of novel biologically based therapeutic strategies in the near future.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16155023     DOI: 10.1200/JCO.2005.55.013

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  23 in total

1.  Hodgkin's disease presenting as discharging neck sinuses and a mediastinal mass.

Authors:  Meira Zolotar; Oladejo Olaleye; Ali Sherif; Rachael Howe; John Mathews
Journal:  BMJ Case Rep       Date:  2011-07-28

2.  Application of MALDI imaging for the diagnosis of classical Hodgkin lymphoma.

Authors:  Kristina Schwamborn; René C Krieg; Peggy Jirak; German Ott; Ruth Knüchel; Andreas Rosenwald; Axel Wellmann
Journal:  J Cancer Res Clin Oncol       Date:  2010-02-21       Impact factor: 4.553

3.  The AP1-dependent secretion of galectin-1 by Reed Sternberg cells fosters immune privilege in classical Hodgkin lymphoma.

Authors:  Przemyslaw Juszczynski; Jing Ouyang; Stefano Monti; Scott J Rodig; Kunihiko Takeyama; Jeremy Abramson; Wen Chen; Jeffery L Kutok; Gabriel A Rabinovich; Margaret A Shipp
Journal:  Proc Natl Acad Sci U S A       Date:  2007-08-01       Impact factor: 11.205

Review 4.  Genomic alterations in Hodgkin's lymphoma.

Authors:  Marc A Weniger; Thomas F E Barth; Peter Möller
Journal:  Int J Hematol       Date:  2006-06       Impact factor: 2.490

5.  The kelch protein KLHDC8B guards against mitotic errors, centrosomal amplification, and chromosomal instability.

Authors:  Maxwell M Krem; Ping Luo; Brandon I Ing; Marshall S Horwitz
Journal:  J Biol Chem       Date:  2012-09-17       Impact factor: 5.157

6.  Tissue-microarray based immunohistochemical analysis of survival pathways in nodular sclerosing classical Hodgkin lymphoma as compared with Non-Hodgkin's lymphoma.

Authors:  Jitakshi De; Robert E Brown
Journal:  Int J Clin Exp Med       Date:  2010-01-30

7.  A Pilot Study of Lenalidomide Maintenance Therapy after Autologous Transplantation in Relapsed or Refractory Classical Hodgkin Lymphoma.

Authors:  Lauren Shea; Marcus P Watkins; Fei Wan; Amanda F Cashen; Nina D Wagner-Johnston; Meagan A Jacoby; Camille N Abboud; John F Dipersio; David D Hurd; Samantha M Jaglowski; Nancy L Bartlett; Todd A Fehniger
Journal:  Biol Blood Marrow Transplant       Date:  2020-08-20       Impact factor: 5.742

8.  Circulating clonotypic B cells in classic Hodgkin lymphoma.

Authors:  Richard J Jones; Christopher D Gocke; Yvette L Kasamon; Carole B Miller; Brandy Perkins; James P Barber; Milada S Vala; Jonathan M Gerber; Lan L Gellert; Mark Siedner; M Victor Lemas; Sarah Brennan; Richard F Ambinder; William Matsui
Journal:  Blood       Date:  2009-02-02       Impact factor: 22.113

Review 9.  The immune microenvironment in Hodgkin lymphoma: T cells, B cells, and immune checkpoints.

Authors:  Santosha Vardhana; Anas Younes
Journal:  Haematologica       Date:  2016-07       Impact factor: 9.941

10.  Inflammation and tissue repair markers distinguish the nodular sclerosis and mixed cellularity subtypes of classical Hodgkin's lymphoma.

Authors:  A Birgersdotter; K R N Baumforth; A Porwit; J Sjöberg; W Wei; M Björkholm; P G Murray; I Ernberg
Journal:  Br J Cancer       Date:  2009-09-22       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.